



Monday, November 11

Level 1, Hall B1, Room 6 // Spotlight Track

14:45	CNS/Neurology	2	Abfero Pharmaceuticals Inc.
15:00	CNS/Neurology	3	Addex Therapeutics [SYM: ADXN]
15:15	CNS/Neurology	PC	PolyNeuroS
15:30	CNS/Neurology	2	Vivoryon Therapeutics AG [SYM: VVY]
15:45	CNS/Neurology	2	Oryzon Genomics, S.A. [SYM: ORY.MC]
16:00	CNS/Neurology	3	AZ Therapies
16:15-17:15	Panel - How to cope: Transversing the neuro path		

Level 1, Hall B1, Room 7 // Therapeutic Area Track

13:30-14:30	Panel - Immuno-oncology: Optimizing success in the crowded partnering market, and trends for 2020		
14:45	Immuno-Oncology	3	I-MAB Biopharma
15:00	Immuno-Oncology	1	Immatix Biotechnologies GmbH
15:15	Immuno-Oncology	1	IGEM Therapeutics Ltd
15:30	Immuno-Oncology	PC	Orion Biotechnology
Break			
16:00-17:00	Panel - Workable business models for AMR innovation		
Break			
17:15	Infectious Diseases	3	Cidara Therapeutics [SYM: CDTX]
17:30	Infectious Diseases	PC	AureoGen Biosciences, Inc.
17:45	Infectious Diseases	1	Atriva Therapeutics GmbH

LEGEND: **D** DISCOVERY **PC** PRE-CLINICAL **1** PHASE 1 **2** PHASE 2 **3** PHASE 3 **IR** IN REVIEW // FOLLOW US AT #BIOEUROPE

Tuesday, November 12

Level 0, Hall B1, Room 3

9:00	Academic Innovators	CHUV HBP MIP
9:10	Academic Innovators	Hospital of the LMU
9:20	Academic Innovators	SOUSEIKAI Global Clinical Research Center
9:30	Academic Innovators	The Institute of Cancer Research, London
9:40	Academic Innovators	University of California, San Diego
9:50	Next Generation	Bionomous
10:00	Next Generation	Cherrykukess
10:10	Next Generation	Gotham Therapeutics
10:20	Next Generation	InveniAI Corporation
10:30	Next Generation	GPN Vaccines Pty Ltd
10:40	Next Generation	Molecule.one
10:50	Next Generation	ADAM
11:00	Next Generation	PharmAI GmbH
11:10	Next Generation	AmpliVak
11:20	Next Generation	GBIOLOGICS
11:30	Next Generation	HepaRegeniX GmbH
11:40	Next Generation	Corea Therapeutics, Inc
11:50	Next Generation	MyNeo
Break		
14:00	Next Generation	Zerion
14:10	Next Generation	Liposphere Ltd
14:20	Next Generation	NIPOKA
14:30	Next Generation	MT-act
14:40	Next Generation	Synendos Therapeutics AG
14:50	Next Generation	Crystera LLC

Level 1, Hall B1, Room 6

9:00	Autoimmune/Inflammation	2	ABIVAX [SYM: ABVX]
9:15	Autoimmune/Inflammation	3	Innovate Biopharmaceuticals, Inc. [SYM: INNT]
9:30	Immunology	2	Immunic, Inc. [SYM: IMUX]
Break			
10:00-11:00	Panel - Digital therapeutic partnership landscape		
Break			
11:15	Cardiovascular	2	Adrenomed AG
11:30	Cardiovascular	1	Kancera [SYM: KAN]
11:45	Cardiovascular	1	Proton LLC [SYM: RVX]

Level 0, Hall B1, Room 4

9:00	Contract Drug Development	Polpharma Biologics
9:15	Contract Drug Development	Boehringer Ingelheim
9:30	Contract Drug Development	Lonza [SYM: LONN]
9:45	Contract Drug Development	Thermo Fisher Scientific [SYM: TMO]
10:00	Dermatology	3 Hovione Scientia Limited
10:15	Ophthalmology	2 OXURION NV [SYM: OXUR]
10:30	Drug Discovery Platform	Anima Biotech Inc
10:45	Pain Management	PC Future Analgesics
11:00	Pain Management	2 Novaremed AG
11:15	Technologies and Tools	US Army Medical Research and Dev. Command
11:30	Technologies and Tools	Nordmark Arzneimittel GmbH & Co. KG
Break		
14:00	Oncology/Autoimmune	Boston Pharmaceuticals
14:15	Oncology	2 VAXIMM
14:30	Oncology	1 Synaffix BV
14:45	Oncology	2 RhoVac [SYM: RHOVAC]
15:00	Oncology	3 Deciphera Pharmaceuticals, Inc. [SYM: DCH]
15:15	Oncology	IR Karyopharm Therapeutics Inc.
15:30	Oncology	Pfenex Inc. [SYM: PFNX]
15:45	Oncology	1 Aptose Biosciences Inc. [SYM: APTO]
16:00	Oncology	1 amcure GmbH
16:15	Oncology	1 Ryvu Therapeutics
16:30	Oncology	2 Oncternal Therapeutics [SYM: ONCT]
16:45	Oncology	1 National OncoVenture

Level 1, Hall B1, Room 7

10:45	Rare and Orphan Diseases	3	Soligenix, Inc. [SYM: SNGX]
11:00	Rare and Orphan Diseases	3	Minoryx Therapeutics
11:15	Metabolic Diseases	1	AptaBio Therapeutics Inc. [SYM: 293780]
11:30	Metabolic Diseases	PC	Phenix AG
11:45	Target & Biomarker Discovery		Euretos AI Platform
Break			
14:00	Drug Discovery and Dev.	PC	Synoesis Therapeutics
14:15	Drug Discovery and Dev.		Covance [SYM: LH]
14:30	Gastrointestinal	IR	RedHill Biopharma [SYM: RDHL]
14:45	Gastrointestinal	2	Synthetic Biologics, Inc. [SYM: SYN]
15:00	Midsize Pharma		Almirall [SYM: ALM]
15:15	Midsize Pharma		Ferring Pharmaceuticals
15:30	Midsize Pharma	2	Debiopharm International SA
15:45	Midsize Pharma	3	Zambon SPA
16:00	Midsize Pharma	D	DuPont Nutrition and Biosciences [SYM: DD]
16:15	Midsize Pharma	IR	CHUGAI PHARMACEUTICAL CO., LTD. [SYM: CHGCF]
16:30	Midsize Pharma	IR	SOBI [SYM: SOBI]
16:45	Midsize Pharma	D	KANEKA [SYM: 4118]

Wednesday, November 13

Level 0, Hall B1, Room 3

9:00	Antibodies	PC	CDR-Life
9:15	Antibodies	IR	Genmab [SYM: GMAB]
9:30	Antibodies		Ajinomoto Co., Inc. [SYM: AJINY]
9:45	Drug Delivery		Nanoform
10:00	Drug Delivery	3	MedinCell [SYM: MEDCL]
10:20	Next Generation		ADCendo ApS
10:30	Next Generation		Cellbox Solution GmbH
10:40	Next Generation		Tridek One
10:50	Next Generation		Colzyx AB
11:00	Next Generation		Corea Therapeutics, Inc.
11:10	Next Generation		OriCiro Genomics
11:20	Next Generation		Single Cell Discoveries

Level 0, Hall B1, Room 4

9:00	Oncology	2	PharmAbcine, Inc. [SYM: 208340]
9:15	Oncology	3	PCI Biotech [SYM: PCB]
9:30	Oncology	2	ORYX Translational Medicine
9:45	Oncology	1	IPS Biopharma/Immunophotonics Switzerland
10:00	Oncology	PC	ARJUNA Therapeutics
10:15	Oncology	1	Camel-IDS
10:30	Oncology	IR	Oasmia Pharmaceutical [SYM: OASM]
10:45	Oncology	PC	LIFT BioSciences
11:00	Oncology	1	AccuRna Inc.
11:15	Oncology	1	AbClon [SYM: 174900]

Level 1, Hall B1, Room 6

9:00-10:00	Panel - Gene therapy valuation and deal trends		
	Break		
10:15	Cell and Gene Therapies	D	OXGENE
10:30	Cell and Gene Therapies	1	MaxCyte, Inc. [SYM: MXCT]
10:45	Cell and Gene Therapies	3	Pluristem Therapeutics [SYM: PSTI]
11:00	Cell and Gene Therapies	PC	Zelluna Immunotherapy AS
11:15	Cell and Gene Therapies	3	Rexgenero Limited
11:30	Cell and Gene Therapies	1	GEMoAB
	Break		
12:00-13:00	Panel - Advanced therapy collaboration and integrated development: The challenges and opportunities		

LEGEND: 2 DISCOVERY PC PRE-CLINICAL 1 PHASE 1
 D PHASE 2 3 PHASE 3 IR IN REVIEW

BIO-EUROPE® OVERVIEW

